Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 ...
Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now. At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc.
Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Gain Therapeutics ( ...
Gain Therapeutics reports Q1 2025 financial results, progressing Phase 1b study of Parkinson's treatment GT-02287, with FDA engagement anticipated. Successful administration of GT-02287, a lead drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results